Lombard Odier Asset Management (USA)’s Fate Therapeutics FATE Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-246,126	Closed	-$768K	–	198
2016 Q3	$768K	Sell	246,126 -10,300	-4%	-$25K	0.07%	214
2016 Q2	$436K	Buy	256,426 +7,052	+3%	+$12.8K	0.05%	187
2016 Q1	$449K	Sell	249,374 -100,932	-29%	-$208K	0.06%	143
2015 Q4	$1.18M	Buy	350,306 +33,218	+10%	+$140K	0.11%	134
2015 Q3	$1.69M	Buy	317,088 +11,607	+4%	+$79.3K	0.15%	148
2015 Q2	$1.98M	Buy	+305,481	New	+$1.83M	0.14%	150

Other funds holding FATE

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s FATE Position: Q4 2016 in Review

Lombard Odier Asset Management (USA) sold out of Fate Therapeutics (FATE) in Q4 2016, closing a stake of 246,126 shares — an estimated $768K sold.

Lombard Odier Asset Management (USA) first reported a position in FATE in Q2 2015 and held it in 6 quarters. The position peaked at $1.98M in Q2 2015. 37 funds tracked by Wall St. Rank hold FATE as of Q4 2016.

Lombard Odier Asset Management (USA) reported no remaining Fate Therapeutics position as of Q4 2016 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 246,126 Fate Therapeutics shares in Q4 2016, an estimated $768K.
Lombard Odier Asset Management (USA) first reported a position in Fate Therapeutics in Q2 2015 and held it in 6 quarters.
Lombard Odier Asset Management (USA)'s Fate Therapeutics position peaked at $1.98M in Q2 2015.
37 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2016.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q4 2016, filed 15 Feb 2017.